Abaloparatide.

Abapatide, a peptide consisting of 34 amino acid residues, is a novel parathyroid hormone-related peptide (PTHrP) developed by RadiusHealth, Inc. which is a potent and selective activator of the PTH-I receptor, increases bone mineral content, bone density, and bone strength, and promotes bone formation, and has been approved for marketing by the FDA on April 28, 2017 under the trade name Tymlos. abapatide is administered subcutaneously for the treatment of osteoporosis in postmenopausal women who are at risk of fracture or who are refractory to other therapeutic agents, and is effective in reducing the rate of new vertebral and nonvertebral fractures. Abapatide provides a better reduction in the fracture rate and the incidence of hypercalcemia compared to teriparatide.

Pls input...